-
Coronavirus Macrodomains and PARP Antiviral Defense
2026-09-19
Grunewald et al. showed that coronavirus macrodomains counter PARP-dependent restriction of viral replication and support appropriate interferon production. Their combination of pharmacologic inhibition, PARP12 and PARP14 depletion, primary macrophages, and animal infection models provides a mechanistic framework for studying ADP-ribosylation in virus–host interactions.
-
Hydroxychloroquine Sulfate Workflow Guide
2026-09-19
Hydroxychloroquine Sulfate (SKU B4874) provides a water-compatible research reagent for probing autophagy pathway modulation and TLR7/9-associated responses in autoimmune disease research. It is suited to short-term aqueous workflows, but should not be selected for DMSO- or ethanol-based stocks or long-term storage of prepared solutions.
-
ddATP as a Replication-Repair Assay Probe
2026-09-18
ddATP is more than a Sanger sequencing reagent: it can function as a mechanistic perturbation tool for studying DNA synthesis during double-strand-break repair. This guide connects its chain-termination chemistry with oocyte break-induced replication research and practical assay design.
-
Hematoxylin and Eosin Staining Kit Guide
2026-09-18
The ready-to-use H&E staining kit supports consistent tissue morphology visualization in paraffin-embedded sections, frozen sections, and cytological preparations. It is intended for scientific research and workflow development, not diagnostic or medical use.
-
Western Secondary Antibody Dilution Buffer
2026-09-17
A scenario-based guide to using Western Secondary Antibody Dilution Buffer (SKU K4115) to improve secondary-antibody consistency when validating cell viability, proliferation, and cytotoxicity findings by Western blot. It connects formulation, reuse, storage, protocol controls, and macrophage inflammation research without overstating what the reagent can prove.
-
PGF2α/PTGFR Controls Endometrial Breakdown
2026-09-17
A 2024 mouse menstrual-like model study identifies PGF2α/PTGFR signaling as a functional regulator of endometrial shedding and vascular permeability after progesterone withdrawal. Its combination of receptor inhibition, vascular readouts, and HIF-1α promoter analysis connects prostaglandin signaling with a defined transcriptional mechanism.
-
Mubritinib (TAK 165): Beyond HER2
2026-09-16
Mubritinib (TAK 165) is best understood as a mechanistically defined mitochondrial complex I inhibitor, not simply a historical HER2 agent. This article connects complex I biology, AML and PEL model selection, cardiac safety, assay design, and translational strategy.
-
Fluorouracil in Breast and Colon Cancer Research
2026-09-15
Fluorouracil and 5-Fluorouracil are valuable mechanistic probes for studying thymidylate synthase, DNA replication, and treatment-response heterogeneity. This article connects compound handling with the SMC2/SMC4 breast cancer findings to improve assay design and interpretation.
-
UV-Fenton Degradation of Sulfisomidine in Real Water
2026-09-15
The reference study moves beyond parent-drug removal by combining UV-Fenton degradation, HPLC-QTOF-MS transformation-product profiling, QSAR prediction, and HepG2 cytotoxicity testing for sulfisomidine and related pharmaceuticals. Its most important practical finding is that a real DTRO-concentrate matrix slowed degradation and that some intermediates temporarily increased toxicity, demonstrating why treatment assessment must include transformation products rather than disappearance of the starting compound alone.
-
TRIM66 and Monogenic Olfactory Receptor Choice
2026-09-14
The reference study identifies TRIM66 as an epigenetic repressor that helps olfactory sensory neurons transition from low-level expression of multiple receptor genes to stable monogenic receptor expression. Its genetic, molecular, neural-activity, and behavioral evidence connects enhancer repression with olfactory circuit function and innate behavior.
-
ABT-199 and the Next Logic of BCL-2-Dependent Apoptosis
2026-09-14
ABT-199, also known as Venetoclax and GDC-0199, offers a highly selective way to interrogate BCL-2 dependence in apoptosis research. This article connects its mechanistic precision with treatment-induced senescence, hematologic malignancy models, and a translational workflow inspired by glioblastoma research.
-
RNA Pol II Loss and Apoptotic Signaling
2026-09-13
Harper and colleagues show that RNA polymerase II inhibition kills cells through an active apoptotic response to depletion of hypophosphorylated RNA Pol IIA, rather than simply through loss of transcription and progressive mRNA decay. The study defines the Pol II degradation-dependent apoptotic response and provides a framework for interpreting transcription-targeting drugs in cancer research and apoptotic pathway research.
-
Canagliflozin: Interpreting a Negative mTOR Screen
2026-09-12
Canagliflozin hemihydrate is best understood not only as an SGLT2 research tool, but also as a useful negative-control boundary in pathway screening. This article connects renal glucose reabsorption inhibition with a 2025 drug-sensitized yeast study to show how negative mTOR results can improve assay interpretation.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Guide
2026-09-12
Use EZ Cap™ Cy5 EGFP mRNA (5-moUTP) to separate cellular uptake from productive translation in one experiment. Its Cy5 signal supports delivery and trafficking measurements, while EGFP reports functional expression across lipid, nanoparticle, and electroporation workflows.
-
Calnexin Shapes CFTR Variant Rescue
2026-09-11
Tedman et al. used deep mutational scanning to show that calnexin controls CFTR surface expression and corrector responsiveness in a variant- and domain-dependent manner. The study provides a framework for interpreting why the F508del mutation and other clinical CFTR variants differ in pharmacological rescue, while highlighting the need to measure proteostasis and channel function separately.